1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

AZ Closer To Second Enhertu OK After Gastric Cancer Success

Improved Overall Survival Compared With Chemo

 
• By Kevin Grogan

The Daiichi Sankyo-partnered antibody drug conjugate has just been approved for breast cancer and AstraZeneca's oncology R&D chief tells Scrip that there are many other HER-2-expressing tumor types where Enhertu has shown potential.

Arrow_Paths
Lots of paths future development of Enhertu may take • Source: Shutterstock

With its recently-approved breast cancer drug Enhertu having succeeded in a gastric cancer trial, AstraZeneca PLC believes that the Daiichi Sankyo Co. Ltd.-partnered HER2-directed antibody-drug conjugate could be a potential therapy for multiple indications.

The company has presented top-line results from the registrational Phase II trial DESTINY-Gastric01 which showed that treatment with Enhertu (trastuzumab...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By Kevin Grogan

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

BioNTech/BMS Bispecific Shows Early Promise In Small Cell Lung Cancer

 
• By Andrew McConaghie

An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger

China-Originated Assets Lead Global GLP-1 Deals

 
• By Xu Hu

The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.